Improving the bioavailability of alendronate sodium using SBA-15 and SBA-16 for osteoporosis and its cytotoxic behavior towards osteosarcoma
摘要
Alendronate Sodium (ALD) is a class III drug according to the Biopharmaceutical Classification (BSC). It is characterized by low bioavailability and limited oral absorption. This limitation can be overcome by developing a controlled drug delivery system using SBA-15 and SBA-16. The synthesized materials were characterized by various physicochemical techniques like FT-IR, TGA, BET, XRD, SEM, and HRTEM. An in vitro release study was carried out in simulated body fluid (pH 7.4) under stirring conditions with two different carriers for their drug delivery potential and compared with the release profile of the marketed formulation, which was further supported by an in vitro dissolution study. To study reaction kinetics and mechanism, different models like zero order, first order, and Higuchi model were used. Taking into account the anti-cancer potential of ALD, cytotoxicity studies were carried out using an osteosarcoma cell line for the synthesized materials.
Graphical abstract